- Announces $200 Million Share Repurchase Program
- Declares Second Quarter Dividend of $0.12/share
- Provides Final Results of Tender Offer
Analysts were anticipating a loss of 14 cents a share on revenue of $7.26 billion.
Shares of this oil refiner could be poised for gains in the months ahead, thanks to pressure from an activist investor.
Horizon Pharma is a 'giant headache,' says Jim Cramer; Abbot Labs is OK long term.
Holiday-shortened week holds a feast of earnings reports, says Jim Cramer.